Breast Cancer News
In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
African-American women were more likely to stop working during the first 2 months of breast cancer treatment compared with non-Hispanic white peers, an analysis found. The study, published in Journal of Cancer Survivorship, assessed racial differences in quality of life and employment after breast cancer diagnosis.
Having very young children may affect whether women receive radiation therapy after breast-conserving surgery.
The American Society of Clinical Oncology published updates to their 2005 guidelines for use of sentinel lymph node biopsy in early-stage breast cancer. The guidelines, based on the review of 9 randomized clinical trials and 13 cohort studies, reflect what ASCO believes are best practices in using the biopsy.
Trust in medical care received, age, and positive attitude are factors that may affect risk for anxiety or depression among black women newly diagnosed with breast cancer, researchers found.
Everolimus (Afinitor) and exemestane (Aromasin) taken at the same time may be an effective first-line treatment for hormone receptor-positive breast cancer that spread beyond the breast to other organs, after treatment with another aromatase inhibitor. This finding comes from a new analysis of data from the BOLERO-2 trial.
Reconstruction of the breasts after their surgical removal to treat breast cancer may improve body image and sexual satisfaction among women, a study published in Psycho-Oncology suggests. Women who had implant-based or deep inferior epigastric artery perforator (DIEP) flap reconstruction experienced great improvement in these areas in the months following either surgery.
Research presented at the 2014 American Association for Cancer Research Annual Meeting suggests a new treatment pair may help double the time before estrogen receptor-positive, metastatic breast cancer grows or spreads.
A recent study suggests that while women are living longer after treatment for breast cancer, they may be at greater risk of developing certain health conditions as they age.
The final analysis of survival data from the Comparison of Faslodex in Recurrent or Metastatic Breast Cancer (CONFIRM) trial is encouraging. Researchers confirmed what was seen as a trend in their initial secondary analysis: postmenopausal women with metastatic, hormone-positive breast cancer lived longer when given twice the past standard amount of fulvestrant (Faslodex).
More and more women are choosing breast reconstruction following mastectomy, partially due to the considerable rise in use of bilateral mastectomy.